Enlivex ENLV 深 滬
已收盤 11-06 16:00:00 美东时间
1.27
0.000
0.00%
華盛通- 最 高1.30
- 今 開1.27
- 成交量 1.81万股
- 最 低 1.23
- 昨 收 1.27
- 總市值 194.56万
- 52周最高 434.40
- 市盈率 靜 0.00
- 換手率 1.18%
- 52周最低 1.22
- 委 比 68.07%
- 總股本 153.20万
- 歷史最高 10776.00
- 量 比 0.24
- 振 幅 5.51%
- 歷史最低 1.23
- 每 手 1
- 風險率 98.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多医药行业10月裁员统计：裁员率最高达94%
进入年底，医药行业裁员消息密集释放。从跨国药企的全球降本计划，到 Biotech 因临床、商业化不及预期被动缩编，一起来看看本月行业裁员事件汇总。 10 月 ...
10-30 17:06
Enlivex Reports 135 Of 182 Planned Patients Randomized And Dosed In Phase 2b Knee Osteoarthritis Trial Of Allocetra; Topline Six-Month Data Expected By Mid-2027
• 135 patients, out of a total planned 182, have been randomized and were administered the first injection of AllocetraTM; enrollment actively ongoing at clinical sites in the United States and in Europe • Topline six-month data expected by mid-2027 • Phase 2b builds on positive three...
10-28 20:01
Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal
Enlivex Ltd. (Nasdaq: ENLV) received a delisting notice from Nasdaq due to its ordinary shares closing bid price falling below $1.00 for 30 consecutive business days. The company, which conducted a reverse share split within the past year, is ineligible for a 180-day compliance period. Enlivex plans to appeal the delisting decision by requesting an oral hearing before the Nasdaq Hearings Panel, which would temporarily suspend delisting actions. T...
10-27 12:00
Enlivex Launches Cost Reduction Plan To Prioritize Phase 2b Allocetra Knee Osteoarthritis Trial, Topline Data Expected By Mid-2027
Non-clinical R&D activities to be wound down; resources to be focused on executing the Phase 2b trial Workforce reduced by approximately 60%; management and CEO salaries reduced Plan designed to substantially reduce cash burn Topline Phase 2b six-month endpoint data expected by mid-2027 Nes-Ziona, I...
10-19 20:20
Enlivex shares are trading lower after the company announced the termination of its agreement to sell 66,666,667 shares to the Rain Foundation in exchange for RAIN tokens.
Enlivex shares are trading lower after the company announced the termination of its agreement to sell 66,666,667 shares to the Rain Foundation in exchange for RAIN tokens.
09-23 01:08
Enlivex Drops RAIN-Token Financing Deal, Halts Planned Private Placement
An announcement from Enlivex ( ($ENLV) ) is now available. Enlivex Ltd., a Nasd...
09-22 20:27
Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens
Enlivex Ltd. (Nasdaq: ENLV) has terminated a securities purchase agreement with the Rain Foundation, under which the Company had agreed to sell 66,666,667 ordinary shares using RAIN tokens in a private placement. The termination was made in accordance with the Company's rights, and no further action will be taken regarding the private placement or shareholder approval. Enlivex is a quality longevity company advancing immunotherapy for age-related...
09-22 12:00
Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says
Enliven Therapeutics Inc. (NASDAQ:ELVN) drew an Outperform rating from William Blair on Tuesday as the firm initiated coverage, citing the potential for lead drug candidate ELVN-001 to reshape treatment of chronic myeloid leukemia (CML). ELVN-001 Shows Positive Phase 1 Data Enliven Therapeutics’ lea...
08-19 01:58
美股前瞻 | 美财长称明日与伊达成协议！道指、标普500指数期货齐创历史新高；光通信概念盘前飙升；SpaceX盘后放榜
美财长称明日与伊达成协议！道指、标普500指数期货齐创历史新高；光通信概念盘前飙升，Lumentum劲升13%；SpaceX盘后放榜！未来指引将“大于”业绩本身？>>
08-04 20:13
美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
